Drug Profile
Research programme: cetuximab companion diagnostic - ANGLE/MD Anderson Cancer Center
Alternative Names: Erbitux companion diagnostic - ANGLE/MD Anderson Cancer CenterLatest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator ANGLE plc; University of Texas M. D. Anderson Cancer Center
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 23 Aug 2023 Discontinued - Preclinical for Colorectal cancer (Diagnosis) in United Kingdom (unspecified route)
- 23 Aug 2023 Discontinued - Preclinical for Colorectal cancer (Diagnosis) in USA (unspecified route)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Colorectal-cancer(Diagnosis) in United Kingdom